Navigation Links
Magnetic Brain Stimulation May Temporarily Dull Nicotine Craving
Date:4/26/2013

By Amy Norton
HealthDay Reporter

FRIDAY, April 26 (HealthDay News) -- Noninvasive stimulation of an area of the brain linked to addiction seems to temporarily ease smokers' cravings for nicotine, a preliminary study finds.

The technique, called transcranial magnetic stimulation (TMS), is already approved in the United States as a treatment for major depression. In the new study, reported in a recent issue of the journal Biological Psychiatry, researchers tested the effects of the treatment on 16 smokers' craving for nicotine.

They found that in general, the smokers were yearning for nicotine after seeing tempting images -- like a person lighting a cigarette. But after 15 minutes of transcranial magnetic stimulation, that craving dipped by almost 30 percent, on average.

But whether brain stimulation could boost smokers' willpower, or ultimately help them quit, is anybody's guess.

"This is just a pilot study," said lead researcher Dr. Xingbao Li, an assistant professor at the Medical University of South Carolina, in Charleston. "There's still a long way left to go."

During TMS, an electromagnetic coil is placed on the scalp to create electric currents that stimulate cells in a specific area of the brain. The therapy is approved for hard-to-treat cases of depression that do not improve with standard treatments, like antidepressants and talk therapy.

Experts think it works by boosting levels of mood-regulating chemicals like dopamine. That may also be what's happening when it comes to nicotine craving, Li explained, since dopamine levels dip when people are in withdrawal from a drug.

But that's speculation for now, he said.

Another researcher who studies tobacco dependence said the findings, while early, are "quite exciting."

If further research supports it, transcranial magnetic stimulation could be one more tool in the smoking-cessation toolbox, according to Christine Sheffer, an associate medical professor of community health and social medicine at the City College of New York.

Sheffer said she could foresee TMS being an option for smokers, to be used along with behavioral counseling. "I think it is important to stress that it is unlikely that any form of brain stimulation -- or any treatment for that matter -- is going to affect cessation without behavioral treatment," Sheffer said.

The findings are based on 16 smokers who had no designs on quitting, but agreed to undergo transcranial magnetic stimulation. First, they all viewed four collections of images, one of which was aimed at boosting their nicotine craving -- like images of a smoker lighting up. After seeing each collection, the smokers rated their nicotine craving.

Afterward, the smokers sat through 15 minutes of the brain stimulation treatment, then looked at the images again and rated their desire for nicotine.

To help ensure that any effects of the transcranial magnetic stimulation were real, Li's team also had each smoker go through the whole process on a separate day, but with a "sham" version of transcranial magnetic stimulation. The fake device looked and sounded like the real thing, and also gave smokers the same sensation in the scalp. But it didn't deliver the electrical current.

Overall, Li's team found, the real transcranial magnetic stimulation reduced smokers' nicotine craving by close to 30 percent. Their cravings also declined after the phony device, but the decline wasn't statistically significant.

"We don't know how significant this would be in real life," Li said.

The next step, he said, is to see whether a series of brain stimulation treatments over a couple weeks has lasting effects on smokers' cravings. The question of whether the brain stimulation could ultimately affect quit rates will take larger, longer term studies.

Based on what's known from depression treatment, transcranial magnetic stimulation seems safe, Li said. The main side effects are a short-lived headache and scalp discomfort. There also appears to be a small risk of seizure, happening in fewer than one in 1,000 patients.

If transcranial magnetic stimulation were to become an option for smokers, there would also be the issue of cost. When the therapy is used for depression, one session typically costs around $300.

Still, Sheffer said that the more options available to smokers, the better. Right now, the approved treatments include nicotine replacement products, like patches and gums, as well as the prescription drugs varenicline (Chantix) and bupropion (Zyban and generics).

Those options, Sheffer noted, are meant to be used along with behavioral counseling.

According to the American Lung Association, it takes the average smoker five or six "serious attempts" to finally quit. So if one approach fails, the group says, keep trying until you find the combination of therapies that works.

More information

The American Lung Association has advice on kicking the habit.

SOURCES: Xingbao Li, M.D., assistant professor, psychiatry and behavioral sciences, Medical University of South Carolina, Charleston; Christine Sheffer, Ph.D., associate medical professor, community health and social medicine, City College of New York; April 15, 2013, Biological Psychiatry


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. New Magnetic Bracelet with Gemstones Announces Superior Magnetics
2. Data Devices International Announces the Introduction of the DataGauss Hard Disk Drive and Magnetic Media Degausser
3. Magnetic Implant May Ease Chronic Acid Reflux
4. Klingg, the Wearable Magnetic Earphone Cord Holder is Released by Mokao Design
5. Into the magnetic resonance scanner with a cuddly toy
6. Is magnetic therapy effective for tinnitus?
7. In-utero exposure to magnetic fields associated with increased risk of obesity in childhood
8. New research confirms efficacy of transcranial magnetic stimulation for depression
9. Voices Against Brain Cancer Responds to Research Identifying New Way Doctors Can Detect Whether Breast Cancer Will Spread to Brain
10. Bipolar Disorder Drugs May Tweak Genes Affecting Brain
11. Ingredient in New MS Drug Linked to Serious Brain Disease
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Magnetic Brain Stimulation May Temporarily Dull Nicotine Craving
(Date:4/24/2017)... ... April 24, 2017 , ... ... opioid overdose deaths now claim the lives of 62 Americans each day.(1) Yet ... against drug manufacturers, distributors, pharmacies and prescribers by more than half.(2) Novus ...
(Date:4/24/2017)... ANGELES, CA (PRWEB) , ... April 24, 2017 , ... ... picture is worth a thousand words. The good news for single women is that ... for Attraction," which is available on April 25th. Joan's insight, personal experiences and sparkling ...
(Date:4/24/2017)... ... ... “Reflections of God’s Work”: an enlightening collection of life lessons leading each ... published author, Jerri Broglin, a survivor of great loss who gained insight on how ... for those searching for answers, as we are finding the answers that are so ...
(Date:4/24/2017)... NC and Seattle, WA (PRWEB) , ... April ... ... utilized by 75+ leading lifestyle brands, work wear distributors and International relief organizations ... they can carry. The company also offers lifestyle and work wear collections via ...
(Date:4/22/2017)... ... April 22, 2017 , ... Ecommerce sales have grown every year since ... $394.9 billion. The consequences of rapid innovation and growth are often neglected in ... it is every business and individual’s job to give something back to the planet ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... Inc ., a digital health company focused on modernizing and ... $25 million in Series B funding led by Qiming US ... Seattle that is part of a broader family ... included participation from SR One , who led ZappRx,s ... Google Ventures). As part of the financing, Mark McDade ...
(Date:4/20/2017)... Research and Markets has announced the ... Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies ... ... was valued at US$ 7,167.6 Mn in 2015, and is ... a CAGR of 5.6% from 2016 to 2024. ...
(Date:4/20/2017)... 20, 2017 NeuroVive Pharmaceutical AB (Nasdaq ... positive preclinical results demonstrating anti-fibrotic effects with ... steatohepatitis (NASH), in an additional well-validated experimental ... has previously shown similar anti-fibrotic effects in ... scientists present novel data demonstrating anti-fibrotic effects ...
Breaking Medicine Technology: